P1, N=60, Recruiting, Anwita Biosciences | N=30 --> 60 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Feb 2025 --> Jun 2026

3 months ago

Enrollment change • Trial completion date • Trial primary completion date

AWT020

6ms

AWT020-001-I: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies (clinicaltrials.gov)

P1, N=214, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • capecitabine • pemetrexed • oxaliplatin • AWT020

9ms

AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity. (PubMed, Front Immunol)

Notably, this selective tumoral T-cell stimulation enables potent tumor-specific T-cell responses, underscoring the molecule's enhanced efficacy and safety. The AWT020 fusion protein offers a promising novel immunotherapeutic strategy by integrating PD-1 blockade and IL-2 signaling, conferring enhanced anti-tumor activity with reduced toxicity.

9 months ago

Journal

CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)

AWT020

10ms

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies (clinicaltrials.gov)

P1, N=214, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.

10 months ago

New P1 trial

Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • capecitabine • pemetrexed • oxaliplatin • AWT020

almost2years

Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)

P1, N=30, Recruiting, Anwita Biosciences | Phase classification: P1/2 --> P1

almost 2 years ago

Phase classification • Metastases

AWT020

2years

Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)

P1/2, N=30, Recruiting, Anwita Biosciences

2 years ago

New P1/2 trial • Metastases

AWT020

3years

A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy (SITC 2022)

Ethics Approval The protocol of animal studies has been reviewed and approved by IACUC. Download figure Open in new tab Download powerpoint Abstract 1104 Figure 1 MOA of AWT020AWT020 is highly specific to tumor infiltrated T cells

3 years ago

Clinical • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • CD3D (CD3d Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)

AWT020